A recent study in Science Advances hones in on the molecular workings of two common types of chimeric antigen receptor (CAR) T cells in cancer treatment. A team led by researchers from Baylor College of Medicine investigated the immune synapse, where CAR T cells interact with cancer cells, to understand how different signaling domains affect anticancer activity.
The study compared CD28.ζ-CART cells and 4-1BB.ζ-CART cells, likening them to sprinters and marathon runners, respectively. CD28.ζ-CART cells exhibit rapid but short-lived cancer-killing activity, while 4-1BB.ζ-CART cells maintain consistent killing over extended periods.
By examining molecular dynamics at the immune synapse, specifically within membrane lipid rafts, the team uncovered distinct behaviors. CD28.ζ-CAR molecules move quickly through the immune synapse, enabling fast cancer cell killing and rapid recovery. This allows for efficient "serial killing" of cancer cells. In contrast, 4-1BB.ζ-CAR molecules linger in lipid rafts and the immune synapse, promoting cell multiplication and "collaborative" tumor cell killing.
Search Antibodies Search Now Use our Antibody Search Tool to find the right antibody for your research. Filter
by Type, Application, Reactivity, Host, Clonality, Conjugate/Tag, and Isotype.
“Observing the distinct pattern of dynamics between single molecules helps us understand the big picture of how these products work,” explained Ahmed Gad, first author of the study. “Next, we are studying how to dynamically adapt these CAR T cells at the synapse level to make them more effective.”
Nabil Ahmed, senior author, emphasized the importance of understanding these molecular-level processes to engineer more effective CAR T cells “Tumors are very sophisticated. We need to adapt our tools to the biology of the disease. This may involve using multiple tools that work in different ways at different stages.”